A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Page 1 of 19 12311 ... LastLast
Results 1 to 10 of 189

Thread: (K) Post-Treatment PSA BCR Adjuvant & Salvage RT

  1. #1

    (K) Post-Treatment PSA BCR Adjuvant & Salvage RT

    Table of Contents
    A title in all caps does not reflect any emphasis; it is simply how it appeared on the page I copied from.
    Studies in red are new additions.
    See also Topic (H) - Radiation Treatment.

    [#1] ASCO GU 2018: Impact of Decipher test on adjuvant and salvage treatments received following radical prostatectomy

    [#2] Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy [2018]

    [#3] Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcomes [2018]

    [#4] High Post-RP PSA level prior to salvage RT is not always a bad sign [2017]

    [#5] Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome [2018]

    [#6] Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy? [2016]

    [#7] Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review [2017]

    [#8] Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? [2016]

    [#9] Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group [2018]

    [#10] Salvage Treatment After Radical Prostatectomy [2018]

    [#11] Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy [2018]

    [#12] Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience [2018]

    [#13] A Framework for Treatment Decision Making at Prostate Cancer Recurrence [2017]

    [#14] Extraprostatic extension (EPE) alone is not enough to justify adjuvant radiation [2016]

    Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins [2016]

    [#15] YOUR PSA IS “UNDETECTABLE”: What Does That Mean? How Does An Undetectable PSA Affect Management? [2015]

    [#16] Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial? [2016]

    Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy [2015]

    SUO 2017: Optimal Timing of Adjuvant and Salvage Radiation Following Radical Prostatectomy [2017]

    [#17] Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis [2017]

    [#18] Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience [2018]

    [#19] SALVAGE RADICAL PROSTATECTOMY VERSUS SALVAGE CRYOTHERAPY FOR LOCALIZED RADIORECURRENT PROSTATE CANCER: COMPARATIVE LONG-TERM OUTCOMES

    [#20] Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis [2018]

    [#21] Prognostic Significance of Lymphovascular Invasion in Clinically Localized Prostate Cancer after Radical Prostatectomy [2008]

    [#22] Salvage radiotherapy after radical prostatectomy: Preserving patient quality of life with modern treatment techniques [2017]

    Functional and oncological outcomes of salvage external beam radiotherapy following robot-assisted radical prostatectomy in a Canadian cohort [2017]

    [#23] The relationship between anxiety about prostate cancer among patients with biochemical cancer recurrence and the use of complementary and alternative medicines, diet, and exercise [2018]

    [#24] Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features [2018]

    [#25] Predictive factors of biochemical recurrence after radical prostatectomy for high‐risk prostate cancer [2018]

    [#26] Long‐term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence [2018]

    [#27] Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™) [2017]

    [#28] Effects of perineural invasion in prostate needle biopsy on tumor grade and biochemical recurrence rates after radical prostatectomy [2018]

    [#29] Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation [2017]

    [#30] Salvage high‐intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi‐institutional analysis of 418 patients [2017]

    [#31] Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy [2018]

    [#32] Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer [2018]

    [#33] Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial [2018]

    [#34] Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy [2018]

    [#35] Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection [2018]

    [#36] Postoperative Hypofractionated Radiotherapy for Prostate Cancer [2018]

    [#37] Relapsing Prostate Cancer: Castrate or Cure? [2018 Case Study]

    [#38] The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: A comparative study of three definitions [2018]

    [#39] Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients [2018]

    [#40] Surgical margin status and its impact on prostate cancer prognosis after radical prostatectomy: a meta-analysis [2018]

    [#41] Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time [2018]

    [#42] Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy [2018]

    [#43] The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer [2018]

    [#44] Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy
    A Systematic Review and Meta-analysis [2018]

    [#45] Prostate Cancer – Local Treatment after Radiorecurrence: Surgery - Back to the future? [2018]

    Prostate Cancer – Local Treatment after Radiorecurrence: Salvage Cryoablation [2018]

    Prostate Cancer – Local Treatment after Radiorecurrence: HIFU – High-Intensity Focused Ultrasound [2018

    [#46] Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes [2018]

    [#47] Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis [2018]

    [#48] The significance of reporting to the thousandths place: Figuring out the laboratory limitations [2017]

    [#49] How soon after surgery should salvage radiation begin? [2017]

    [#50] Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen [2017]

    Prostate Specific Antigen Testing after Radical Prostatectomy—Can We Stop at 20 Years? [2018]

    [#51] Risk of biochemical recurrence (BCR) in prostate cancer (PCa) patients (pts) with perineural invasion (PNI): Systematic review and meta-analysis [2018]

    [#52] The prognostic value of mid-treatment prostate-specific antigen level in patients receiving salvage radiotherapy [2018]

    [#53] Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer [2018]

    [#54] Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer–specific Mortality: Competition Between Age and Time to Biochemical Failure [2018]

    [#55] Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time [2018]

    [#56] Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis [2017]

    Balancing Risks in Prostate-specific Antigen Recurrence: The Fox Versus the Hedgehog [2017]

    [#57] CAN FREE PSA BE USED AS A BIOMARKER IN BIOCHEMICAL RECURRENCE AFTER SURGERY TO PREDICT CASTRATE RESISTANT PROSTATE CANCER? [2018]

    [#58] Establishment of the optimal follow-up schedule after radical prostatectomy [2018]

    [#59] Who benefits most from early salvage radiation therapy after prostatectomy? [2018]


    TOC Continues Below
    Last edited by DjinTonic; 06-20-2019 at 12:47 PM.

  2. #2

    Table of Contents

    [#60] Usefulness of ultra-sensitive prostate-specific antigen following radical prostatectomy [2014]

    [#61] Factors predicting biochemical recurrence after radical prostatectomy among patients with clinical T3 prostate cancer [2018]

    [#62] 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy [2018]

    Prostate-Specific Membrane Antigen-Negative Metastases-A Potential Pitfall in Prostate-Specific Membrane Antigen PET [2018]

    68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study [2018]

    68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy [2018]

    [#63] PSA-recurrence after radical prostatectomy for intermediate/high risk prostate cancer: A helpful parameter or just a patient stress amplifier[2017]

    [#64] Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits [2018]

    [#65] Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival [2018]

    [#66] OBESITY, RISK OF BIOCHEMICAL RECURRENCE, AND PSADT AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE [2018]

    [#67] Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer [2018]

    [#68] Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma [2018]

    [#69] THE CLINICAL EFFICACY OF PSMA PET/MRI IN BIOCHEMICALLY RECURRENT PROSTATE CANCER COMPARED WITH STANDARD OF CARE IMAGING MODALITIES - RESULTS OF A MULTI-CENTRE, PROSPECTIVE CLINICAL TRIAL [2018]

    [#70] Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management [2017]

    [#71] Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy [2018]

    [#72] Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy [2018]

    [#73] Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies [2018]

    [#74] Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy [2017]

    Biochemical recurrence risk high 10 years post-RP [2017]

    [#75] Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis [2017]

    Extranodal Extension in Lymph Node–Positive Prostate Cancer [2000]

    [#76] One-year experience with 68Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer [2018]

    [#77] The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis [2018]

    [#78] Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer [2018]

    [#79] Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical recurrence in men with organ confined prostate cancer [2018]

    [#80] Perineural invasion as an independent predictor of biochemical recurrence in prostate cancer following radical prostatectomy or radiotherapy: a systematic review and meta-analysis [2018]

    [#81] Salvage robotic-assisted radical prostatectomy: oncologic and functional outcomes from two high-volume institutions [2018]

    [#82] SALVAGE RADIATION THERAPY FOR RECURRENT PROSTATE CANCER: CAN THE PROGNOSTIC GRADE GROUP SYSTEM INFORM TREATMENT TIMING? [2018]

    [#83] A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer [2018]

    Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer [2018]

    [#84] WHEN CAN BIOCHEMICAL RECURRENCE BE CONSIDERED A SURROGATE FOR HARDER CLINICAL ENDPOINTS IN HIGH RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL, LONG-TERM ANALYSES [2018]

    [#85] Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series [2018]

    [#86] Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer [2018]

    [#87] 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients [2018]

    Prostate cancer imaging: when the game gets tough, the hard one gets done! [2018]

    [#88] Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy [2018]

    [#89] The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy [2018]

    [#90] 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning [2018]

    [#91] The perineural invasion paradox: Is perineural invasion an independent prognostic indicator of biochemical recurrence risk in patients with pT2N0 prostate cancer? [2018]

    [#92] Adjuvant Radiotherapy Versus Wait-and-See Strategy for Pathologic T3 or Margin-Positive Prostate Cancer: A Meta-Analysis [2018]

    [#93] Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy [2018]

    [#94] Immediate vs. Delayed ADT for Recurrent Prostate Cancer [2018]

    [#95] Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis [2018]

    [#96] Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy [2018]

    [#97] 68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high‐risk prostate cancer [2018]

    [#98] Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival [2018]

    [#99] Extent of Extraprostatic Extension Independently Influences Biochemical Recurrence-free Survival: Evidence for Further pT3 Subclassification [2015]

    [#100] Who can benefit from postoperative radiotherapy following biochemical recurrence after radical prostatectomy?—looking for the “Rosetta Stone” of prostate cancer [2018]

    Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis [2017]

    [#101] Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy [2018]

    [#102] Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management [2018]

    [#103] The Prostate Clinical Outlook (PCO) Classifier Application for Predicting Biochemical Recurrences in Patients Treated by Stereotactic Body Radiation Therapy (SBRT) [2018]

    [#104] Ultra-sensitive PSA Following Prostatectomy Reliably Identifies Patients Requiring Post-Op Radiotherapy [2014]

    [#105] Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer [2018]

    [#106] Late Biochemical Recurrence Post‐Prostatectomy is Associated with a Slower Rate of Progression [2018]

    [#107] Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT† randomized control trial [2018]

    [#108] Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer [2018]

    [#109] The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients with pT2N0R0 Prostate Cancer? A Multi-Institutional Study
    [2018]

    Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study [2015]

    [#110] Prognostic significance of six clinicopathological features for biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis [2018]

    [#111] Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer [2018]

    [#112] Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review [2018]


    TOC Continues Below
    Last edited by DjinTonic; 12-25-2018 at 11:36 PM.

  3. #3

    Table of Contents

    [#113] Ultrasensitive prostate‐specific antigen level as a predictor of biochemical progression after robot‐assisted radical prostatectomy: Towards risk adapted follow‐up [2018]

    [#114] Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer—Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control [2018]

    [#115] A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer [2018]

    [#116] Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models [2018]

    Re-irradiation for isolated local recurrence of prostate cancer: MONO-INSTITUTIONAL series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT) [2018]

    [#117] Patterns of Recurrence After Salvage Radiotherapy Encompassing Pelvic Lymphatics in Men with High-risk Prostate Cancer [2018]

    [#118] Optimal Post-Radical Prostatectomy Follow-up Schedule Proposed [2018]

    ESTABLISHMENT OF THE OPTIMAL FOLLOW-UP SCHEDULE AFTER RADICAL PROSTATECTOMY [2018]

    [#119] Does race predict the development of metastases in men who receive androgen‐deprivation therapy for a biochemical recurrence after radical prostatectomy? [2018]

    [#120] Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer [2018]

    [#121] Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction [2018]

    [#122] Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer [2018]

    [#123] Salvage radiation therapy for prostate cancer patients after prostatectomy [2019]

    [#124] Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies [2019]

    [#125] Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy [2019]

    [#126] Prognostic significance of the presence of tertiary Gleason grade 5 in robot-assisted radical prostatectomy specimens in Japanese patients with clinically localized prostate cancer [2019]

    [#127] Postoperative Radiation Therapy in Localized Prostate Cancer: When, How Much, and How Fast? [2019]

    [#128] Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery [2019]

    [#129] Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes [2019]

    [#130] Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics? [2019]

    [#131] Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis

    [#132] STEREOTACTIC REIRRADIATION FOR LOCAL RECURRENCE IN THE PROSTATIC BED AFTER PROSTATECTOMY: PRELIMINARY RESULTS [2019]

    [#133] Timing of PSA Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence [2017]

    [#134] Adjuvant Therapy in High-Risk Prostate Cancer [2019]

    [#135] Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis [2019]

    [#136] First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology [2018]

    [#137] Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer [2019]

    [#138] Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy [2019]

    [#139] Impact of Multifocality and Multilocation of Positive Surgical Margin After Radical Prostatectomy on Predicting Oncological Outcome [2019]

    [#140] Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis [2019]

    [#141] Salvage cryotherapy versus salvage radical prostatectomy for radiorecurrent prostate cancer: Long-term oncologic outcomes [2019]

    [#142] Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy [2019]

    [143] What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series [2019]

    [#144] Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review [2019]

    [#145] Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies [2019]

    [#146] WHICH PATIENTS SHOULD BE CANDIDATES FOR ADJUVANT RADIOTHERAPY FOLLOWING RADICAL PROSTATECTOMY? [2019]

    [#147] IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL [2019]

    [#148] TYPE OF PATIENTS IN WHOM BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY CAN BE OBSERVED WITHOUT SALVAGE THERAPY [2019]

    [#149] Recurrence in prostate cancer: salvage diagnostic and therapeutic strategies [2019]

    [#150] How does 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? [2019]

    [#151] Significance and management of positive surgical margins at the time of radical prostatectomy [2014]

    [#152] A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer [2019]

    [#153] Does seminal vesicle-sparing robotic radical prostatectomy influence postoperative prostate-specific antigen measured with an ultrasensitive immunoassay? [2018]

    [#154] Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis from CaPSURE [2019]

    [#155] Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncologic and functional outcomes [2019]

    [#156] Prognostic roles of extraprostatic extension in evaluating biochemical recurrence after radical prostatectomies: PRISMA-compliant systematic review and meta-analysis [2019]

    [#157] Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer [2019]

    [#158] Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography [2019]

    [#159] Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation [2019]

    [#160] Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy [2019]

    [#161] 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical persitence after radical prostatectomy. Detection of cancer locations and impact on subsequent therapy

    Can 68Ga PSMA PET/CT be useful in assessment of response to treatment in patients with carcinoma prostate? [2019]

    [#162] MULTIFOCALITY AND MULTILOCATION OF POSITIVE MARGINS PREDICT BIOCHEMICAL RECURRENCE OF PROSTATE CANCER [2018]

    [#163] Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer [2018]

    [#164] 68Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study [2019]

    [#165] Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations [2019]

    [#166] Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer [2019]

    Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients [2015]

    [#167] Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy [2019]

    [#168] Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study [2017]

    [#169] Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer [2019]

    Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy [2017]

    [#170] Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy [2019]

    Partial Prostate Cancer Treatment for Aggressive Disease—Common Practice [2019]

    [#173] Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings [2017]


    TOC Continues Below
    Last edited by DjinTonic; 08-08-2019 at 04:01 PM.

  4. #4

    Table of Contents

    [#174] Do all men with pathological Gleason score 8–10 prostate cancer have poor outcomes? Results from the SEARCH database [2015, Full Text]

    [#175] Salvage stereotactic body radiotherapy for local prostate cancer recurrence after radiotherapy: a retrospective multicentre study of the GETUG [2019]

    Since August:

    [#176]Detection rate and localization of prostate cancer recurrence using 68Ga-PSMA-11 PET/MRI in patients with low PSA values ≤ 0.5 ng/ml [2019]

    [#177] Nomograms Predict Survival Advantages of Gleason Score 3+4 Over 4+3 for Prostate Cancer: A SEER-Based Study [2019]

    [#178] Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526) [2019]

    [#179] Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy [2019]

    [#180] The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions [2019]

    [#181] Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How? [2019]




    Last edited by DjinTonic; 08-17-2019 at 01:40 PM.

  5. #5
    [Table of Contents p.5]

  6. #6
    [#1]
    ASCO GU 2018: Impact of Decipher test on adjuvant and salvage treatments received following radical prostatectomy
    [ASCO GU 2018 PROSTATE CANCER -- Conference Presentation, 2018]

    https://www.urotoday.com/conference-...tatectomy.html

    Journal version: http://ascopubs.org/doi/abs/10.1200/...36.6_suppl.112


    Discusses treatment decisions and anxiety levels with regard to Decipher test results.
    Last edited by DjinTonic; 07-20-2018 at 05:33 PM.

  7. #7
    [#2]
    Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy [2018, Full Text]

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765929/

    Abstract

    PURPOSE
    Prostate multiparametric magnetic resonance imaging (mpMRI) has utility in detecting post-radiotherapy local recurrence. We conducted a multireader study to evaluate the diagnostic performance of mpMRI for local recurrence after low dose rate (LDR) brachytherapy.

    METHODS
    A total of 19 patients with biochemical recurrence after LDR brachytherapy underwent 3T endorectal coil mpMRI with T2-weighted imaging, dynamic contrast-enhanced imaging (DCE) and diffusion-weighted imaging (DWI) with pathologic confirmation. Prospective reads by an experienced prostate radiologist were compared with reads from 4 radiologists of varying experience. Readers identified suspicious lesions and rated each MRI detection parameter. MRI-detected lesions were considered true-positive with ipsilateral pathologic confirmation. Inferences for sensitivity, specificity, positive predictive value (PPV), kappa, and index of specific agreement were made with the use of bootstrap resampling.

    RESULTS
    Pathologically confirmed recurrence was found in 15 of 19 patients. True positive recurrences identified by mpMRI were frequently located in the transition zone (46.7%) and seminal vesicles (30%). On patient-based analysis, average sensitivity of mpMRI was 88% (standard error [SE], 3.5%). For highly suspicious lesions, specificity of mpMRI was 75% (SE, 16.5%). On lesion-based analysis, the average PPV was 62% (SE, 6.7%) for all lesions and 78.7% (SE, 10.3%) for highly suspicious lesions. The average PPV for lesions invading the seminal vesicles was 88.8% (n=13). The average PPV was 66.6% (SE, 5.8%) for lesions identified with T2-weighted imaging, 64.9% (SE, 7.3%) for DCE, and 70% (SE, 7.3%) for DWI.

    CONCLUSION
    This series provides evidence that mpMRI after LDR brachytherapy is feasible with a high patient-based cancer detection rate. Radiologists of varying experience demonstrated moderate agreement in detecting recurrence.
    [Emphasis mine]

    First Forum post: https://www.cancerforums.net/threads/54326-mpMRI-for-detecting-local-recurrence-in-setting-of-BCR-after-low-dose-brachy

  8. #8
    [#3]
    Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcomes [2018]

    http://journal.waocp.org/?sid=Entrez:PubMed&id=pmid:29374406&key=2018.19.1. 229
    For Full Text click PDF at upper right.

    Discusses using circulating prostate cells (CPCs) and bone marrow micro-metastasis (mM) assayed 1 month post-RP as prognosticators. They modified procedures used in previous, less successful studies.

    Abstract

    INTRODUCTION:
    Minimal residual disease (MRD) remaining after curative therapy for prostate cancer has the potential for growth and can result in metastasis. Circulating prostate cells (CPCs) and bone marrow micro-metastasis (mM) could represent different types of MRD. We here determined; biochemical failure free survival rates; time to BF after 10 years follow-up; and the presence of CPCs and mM in patients treated with radical prostatectomy (RP) for prostate cancer.

    METHODS AND PATIENTS:
    One month after RP, blood and bone marrow were sampled for assessment of CPCs and mM. Cases were classified as: group A, CPC negative and mM negative; group B, CPC negative and mM positive; Group C, CPC positive and mM negative; and Group D, CPC positive and mM positive. Subjects were followed with serial determination of PSA levels, recording the time at which BF occurred defined as a serum PSA >0.2ng/ml. After ten years of follow-up Kaplan-Meier survival curves were generated and the restricted mean survival time (RMST) for each group calculated.

    RESULTS:
    A total of 321 men participated, 140 in group A with survival of 92.7% (86.3 to 96.2), 39 in group B with 55.8% (37.2 to 70.9); 54 in group C with 6.41% (1.19 to 18.21) and 88 in group D with 4.96%(1.64 to 11.13%. The RMST (in years) were: group A, 9.47 (9.24 to 9.69); group B, 9.23 (8.87 to 9.58 ); group C, 4.62 (4.46 to 4.77); and group D, 3.57 (3.52 and 3.63) (p-value<0.001 between groups: A versus C and D, B versus C and D).

    CONCLUSIONS:
    CPC positive men have more aggressive disease, with increased early failure; men who are only positive for mM are at greater risk of late failure. These two forms of MRD represent different clinical entities with respect to biochemical failure and could be used to guide clinical treatment decisions.
    From full text:

    The median Gleason score was 6 and the median pathological stage was pT2
    ..
    The results of this study show that there are two types of minimal residual disease, which can be detected before total serum PSA increases.
    ...
    The detection of CPCs and mM using standard immunocytochemistry does not require high cost technology and can be implemented in the routine immunocytochemical laboratory of a district hospital and the results seem to indicate that clinically useful information is obtained. Further studies are required to determine whether or not treatment selections based on CPC and mM improve treatment results.
    [Emphasis mine]

    First Forum post: https://www.cancerforums.net/threads/54197-Residual-Disease-Post-RP-Implications-amp-Outcomes-(Circulating-Cells-and-Micro-Mets)

  9. #9
    [#4]
    High Post-RP PSA level prior to salvage RT is not always a bad sign [2017]

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737348/

    Case study with 2 patients. Shows value of MRI.
    First: G3+4, PSA Pre-Op 7.1; Post-RP: 0.1→1.59 over 11 yrs;
    Second: G3+4, PSA Pre-Op 7.8; Post-RP 0.1→6.5 over 11 yrs (refused workups)

    Although radical prostatectomy is a popular treatment modality for clinically localized prostate cancer, 10-year biochemical recurrence can reach 28%. Before salvage radiation therapy (SRT), prostate-specific antigen (PSA) values alone should be used cautiously in predicting SRT eligibility. A long, slow PSA rise may suggest locally confined disease still amenable to SRT; corresponding imaging to identify potential gross recurrence is useful. Patients with local disease may safely benefit from higher doses of radiation...

    SRT can be curative in patients with biochemical recurrence following RP7; however, less than half of patients who receive a post-RP secondary therapy of some sort will receive SRT.8 It is important to note that all men may not benefit from SRT, particularly those with findings suggestive of systemic disease. In this setting, balancing potential benefits against therapeutic toxicities and underlying comorbidities can be challenging and significant differences in practice between urologist and radiation oncologist recommendations for post-RP radiotherapy exist...

    Here we present two patients with biochemical recurrence after RP. Both present with high PSA values (some practitioners choose to forego referral for SRT with PSA values this high). Both patients had MRI demonstrating evidence of gross disease in the prostatic fossa and were treated with an integrated boost, as standard doses were thought to be insufficient...

    Main Points
    • Before salvage radiation therapy (SRT), prostate-specific antigen (PSA) values should be used cautiously in predicting SRT eligibility. Incorporating the pattern of PSA rise is recommended. A long, slow PSA rise may suggest locally confined disease still amenable to SRT.
    • Postprostatectomy PSA rise should be evaluated with magnetic resonance imaging (MRI) to identify potential gross local recurrence, which may respond to SRT. Although no minimum PSA threshold for initiating MRI has been established, many clinicians will use PSA kinetics and value at presentation to guide decision making.
    • Radiographically identified gross recurrence may benefit from higher than standard radiation doses.
    First Forum post: https://www.cancerforums.net/threads/53885-High-Post-RP-PSA-level-prior-to-salvage-RT-is-not-always-a-bad-sign-2-Case-Studies

  10. #10
    [#5]
    Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome [2018]

    https://www.ncbi.nlm.nih.gov/pubmed/29374406
    For Full Text: click on Full Text Link at upper right; then, on journal page, click PDF at upper right.

    Discusses using circulating prostate cells (CPCs) and bone marrow micro-metastasis (mM) assayed 1 month post-RP as prognosticators. They modified procedures used in previous, less successful studies.

    Abstract

    INTRODUCTION:
    Minimal residual disease (MRD) remaining after curative therapy for prostate cancer has the potential for growth and can result in metastasis. Circulating prostate cells (CPCs) and bone marrow micro-metastasis (mM) could represent different types of MRD. We here determined; biochemical failure free survival rates; time to BF after 10 years follow-up; and the presence of CPCs and mM in patients treated with radical prostatectomy (RP) for prostate cancer.

    METHODS AND PATIENTS:
    One month after RP, blood and bone marrow were sampled for assessment of CPCs and mM. Cases were classified as: group A, CPC negative and mM negative; group B, CPC negative and mM positive; Group C, CPC positive and mM negative; and Group D, CPC positive and mM positive. Subjects were followed with serial determination of PSA levels, recording the time at which BF occurred defined as a serum PSA >0.2ng/ml. After ten years of follow-up Kaplan-Meier survival curves were generated and the restricted mean survival time (RMST) for each group calculated.

    RESULTS:
    A total of 321 men participated, 140 in group A with survival of 92.7% (86.3 to 96.2), 39 in group B with 55.8% (37.2 to 70.9); 54 in group C with 6.41% (1.19 to 18.21) and 88 in group D with 4.96%(1.64 to 11.13%. The RMST (in years) were: group A, 9.47 (9.24 to 9.69); group B, 9.23 (8.87 to 9.58 ); group C, 4.62 (4.46 to 4.77); and group D, 3.57 (3.52 and 3.63) (p-value<0.001 between groups: A versus C and D, B versus C and D).

    CONCLUSIONS:
    CPC positive men have more aggressive disease, with increased early failure; men who are only positive for mM are at greater risk of late failure. These two forms of MRD represent different clinical entities with respect to biochemical failure and could be used to guide clinical treatment decisions.
    From full text:

    The median Gleason score was 6 and the median pathological stage was pT2
    ..
    The results of this study show that there are two types of minimal residual disease, which can be detected before total serum PSA increases.
    ...
    The detection of CPCs and mM using standard immunocytochemistry does not require high cost technology and can be implemented in the routine immunocytochemical laboratory of a district hospital and the results seem to indicate that clinically useful information is obtained. Further studies are required to determine whether or not treatment selections based on CPC and mM improve treatment results.
    [Emphasis mine]

    First Forum post: https://www.cancerforums.net/threads/54197-Residual-Disease-Post-RP-Implications-amp-Outcomes-(Circulating-Cells-and-Micro-Mets)

 

Similar Threads

  1. Replies: 6
    Last Post: 10-10-2017, 06:10 PM
  2. Criteria for RT after RP: Adjuvant vs. Salvage
    By DjinTonic in forum Prostate Cancer Forum
    Replies: 28
    Last Post: 10-06-2017, 03:30 PM
  3. Adjuvant or Salvage radiation treatment?
    By maxphunn in forum Prostate Cancer Forum
    Replies: 6
    Last Post: 11-15-2016, 01:41 PM
  4. Adjuvant vs. Salvage
    By AIO in forum Prostate Cancer Forum
    Replies: 16
    Last Post: 07-26-2012, 11:42 PM
  5. Adjuvant vs salvage radiation??
    By slkret in forum Prostate Cancer Forum
    Replies: 11
    Last Post: 04-17-2009, 04:40 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •